Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

Chengdu Brilliant Biopharmaceutical Co., Ltd.

Has Chengdu Brilliant Biopharmaceutical Co., Ltd. received an FDA warning letter? Yes. FDA issued a warning letter dated September 11, 2025 concerning products containing semaglutide.

Letter facts

Letter date
September 11, 2025 (2025-09-11)
Issuing office
Center for Drug Evaluation and Research (CDER)
Recipient type
Manufacturer / API
Products named
Active pharmaceutical ingredients (APIs)Semaglutide
Violation categories
CGMP / insanitary conditions

Understanding these violation categories

CGMP / insanitary conditions

FDA says it observed conditions or manufacturing practices that do not meet current good manufacturing standards, potentially risking product sterility or quality. A warning letter allows the facility to provide corrective actions.

Factual Violation Summary

FDA cited failure to conduct process validation for GLP-1 API semaglutide and failure to perform identity testing on incoming raw materials, rendering APIs adulterated under CGMP; Import Alert 66-40 issued July 9, 2025.

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • Process validation
  • Incoming raw material identity testing

More letters about Semaglutide

Recent FDA warning letters concerning Semaglutide:

Similar violations (CGMP / insanitary conditions)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.